Rejas Javier, Ribera María Victoria, Ruiz Manuel, Masrramón Xavier
Health Outcomes Research Department, Medical Unit, Pfizer España, Madrid, Spain.
Eur J Pain. 2007 Apr;11(3):329-40. doi: 10.1016/j.ejpain.2006.05.002. Epub 2006 Jun 12.
This study assessed the psychometric properties of the MOS Sleep Scale in neuropathic pain (NeP).
Psychometric properties were tested in patients with neuropathic pain enrolled in a prospective study exploring the effectiveness of gabapentin for 3 months. Participants also completed scales for pain intensity, anxiety, depression, disability, and health-related quality of life. Feasibility, reliability, validity and sensitivity to change were measured in this study.
Six-hundred-three patients [58.4+/-14.4 years (65.1% female), mean+/-SD] with pain for 1.2+/-3.3 years were included. The MOS Sleep Scale was acceptable (items with missing data <10% and floor and ceiling effects <50% per item and <15% per domain) and reliable (Cronbach's alpha between 0.64 and 0.87, and test-retest intraclass correlation coefficients between 0.79 and 0.91, p<0.001 for all cases). After adjusting for confounders, the MOS Sleep Scale was able to distinguish between sex, present pain intensity, level of disability and presence of anxiety or depression. Correlations with other scales were moderate; rho-coefficients between -0.21 and 0.57 (p<0.01, all cases). The scale was sensitive to change after treatment with gabapentin; after adjusting, responders (50% reduction in baseline pain) showed a decrease in sleep problems index of -25.6+/-14.3 points vs. -12.1+14.5 points in nonresponders (F=80.5, df=1/398, p<0.0001). Score reduction in summary index and subscales correlated significantly with pain intensity reduction (Pearson r-coefficients between 0.428 and 0.116, p<0.01, all cases).
The MOS Sleep Scale showed good psychometric properties and was sensitive to changes in patients with NeP of broad aetiology.
本研究评估了神经病理性疼痛(NeP)患者中MOS睡眠量表的心理测量特性。
在一项探索加巴喷丁3个月有效性的前瞻性研究中,对神经病理性疼痛患者的心理测量特性进行了测试。参与者还完成了疼痛强度、焦虑、抑郁、残疾和健康相关生活质量的量表。本研究测量了可行性、可靠性、有效性和对变化的敏感性。
纳入了603例患者[年龄58.4±14.4岁(65.1%为女性),均值±标准差],疼痛时间为1.2±3.3年。MOS睡眠量表是可接受的(缺失数据的项目<10%,每个项目的地板效应和天花板效应<50%,每个领域<15%)且可靠(Cronbach's α在0.64至0.87之间,重测组内相关系数在0.79至0.91之间,所有情况p<0.001)。在调整混杂因素后,MOS睡眠量表能够区分性别、当前疼痛强度、残疾程度以及焦虑或抑郁的存在情况。与其他量表的相关性为中等;rho系数在-0.21至0.57之间(所有情况p<0.01)。该量表对加巴喷丁治疗后的变化敏感;调整后,有反应者(基线疼痛减轻50%)的睡眠问题指数下降了-25.6±14.3分,而无反应者下降了-12.1±14.5分(F=80.5,自由度=1/398,p<0.0001)。总指数和子量表的得分降低与疼痛强度降低显著相关(Pearson r系数在0.428至0.116之间,所有情况p<0.01)。
MOS睡眠量表显示出良好的心理测量特性,并且对病因广泛的神经病理性疼痛患者的变化敏感。